Novavax, Inc. and SK bioscience, Co., a vaccine subsidiary of Korea-based SK Group, received approval from South Korea’s Ministry of Food and Drug Safety (MFDS) for SK bioscience’s Biologics License Application (BLA) for Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted) for immunization in individuals 18 and older for the prevention of COVID-19 caused by SARS-CoV-2. Nuvaxovid, Novavax’ COVID-19 vaccine also known as NVX-CoV2373, is the first protein-based COVID-19 vaccine to be ap...